tbuckley/cabot-search huggingface dataset:
Abstract 186: Sex Differences in Outcomes for Out-Of-Hospital Cardiac Arrest
Authors: Pavitra Kotini-Shah, Oksana Pugach, Ruizhe Chen, Marina Del Rios, Kimberly Vellano, Bryan F McNally, Terry L Vanden Hoek, Paul Chan
Journal: Circulation (2019)

Introduction: Approximately 1,000 out-of-hospital cardiac arrest (OHCA) occur per day in the United States. Although survival rates remains low, the extent to which OHCA neurological outcomes differ between men and women remains poorly characterized. Methods: Within the national Cardiac Arrest Registry to Enhance Survival (CARES) registry, we identified 195,722 adult individuals with an OHCA between 2013-2017. Using multi-variable logistic regression models, we evaluated for sex differences in rates of survival to hospital discharge and favorable neurological outcome (survival with discharge CPC score of 1 or 2), adjusted for cardiac arrest characteristics, race, location, year of arrest, age, and use of targeted temperature management (TTM) and coronary angiography. Results: Overall, 70,767 (31%) patients were women. Median age was 64 and 62 years for women and men, respectively. An initial shockable rhythm (14.9% vs. 25.7%) and a witnessed arrest (40.9% vs. 45.6%) was more common in men. Bystander CPR was provided to 37% of women and 39% of men. Men were less likely to survive to hospital discharge than women (8.7% vs. 10.9%; adjusted OR 0.75, 95% CI 0.73, 0.78). Similarly, men were less likely to have favorable neurological outcome (6.6% vs. 9.2% for women; adjusted OR 0.78, 95% CI 0.74, 0.82). Further interaction analysis for the pre-hospital elements found small, but statistically significant sex differences in favorable neurological survival for witnessed status (among female OR 2.29, 95% CI 2.10, 2.49; among males OR 2.07, 95% CI 1.92, 2.23, p= 0.04) and for bystander CPR (among females OR 1.20, 95% CI 1.11, 1.29; among males OR 1.34, 95% CI 1.27, 1.42, p= 0.01). Interaction of sex with the hospital level variables of TTM and coronary angiography, for the subset of patients that survived to hospital admission, had no sex differences in favorable neurological outcome. Conclusion: Our analysis shows that for OHCA in the United States, women have better survival outcomes than men. There was a sex differences in the pre-hospital variable of BCPR, but not in the other modifiable variables of TTM and coronary angiography. Further study is needed to better understand sex differences in overall survival and neurological outcomes.
CHANGES IN WALL MORPHOLOGY AND STIFFNESS OF SAPHENOUS-VEIN GRAFTS ONE-YEAR AFTER AORTOCORONARY BYPASS-SURGERY - SERIAL INTRAVASCULAR ULTRASOUND ASSESSMENT IN-VIVO
Authors: Maeda K, Yamaura Y, Akasaka T, Yoshida K, Yoshikawa J, Hozumi T
Journal: Journal of the American College of Cardiology (1994)
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Authors: Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Delvys Rodriguez-Abreu, Laura Galvez-Carvajal, Mariano Provencio, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Marylene Lejeune, Tomás Álvaro, Victor Sánchez-Margalet, Luis de la Cruz-Merino
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or regulatory T cells (Tregs), are recruited by tumors, jeopardizing antitumor immunosurveillance. In this work, we have studied blood levels of these immunosuppressive cells in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), prior to and along the course of the experimental rituximab, gemcitabine, dexamethasone, and cisplatin (R2-GDP) schedule, as a translational substudy of the R2-GDP-GOTEL trial (EudraCT Number: 2014-001620-29), which included lenalidomide as an immunomodulator. Methods Blood samples were taken before treatment, at cycle 3 and end of induction. Samples were analyzed by flow cytometry. Non-parametric tests were used. Mann-Whitney U test was used to compare basal cells distributions, and Wilcoxon test was considered to compare cells distribution at different times. Spearman test was performed to measure the degree of association between cell populations. Results In this study, MDSC and Treg circulating concentration was found increased in all patients compared with a healthy control group and decreased after treatment only in patients with longest overall survival (&gt;24 months), reaching the levels of the healthy group. Likewise, the number of inhibited T lymphocytes expressing Programmed Death-1 (PD-1) were increased in peripheral blood from patients and decreased on the treatment, whereas activated T lymphocytes increased after therapy in those with better overall survival. Conclusions In conclusion, blood concentration of MDSCs and Treg cells may be good prognostic markers for overall survival after 2 years in R/R DLBCL. These results point to a possible role of these elements in the immunosuppression of these patients, as assessed by the circulating activated and inhibited T lymphocytes, and therefore, they may be considered as therapeutic targets in DLBCL.
De Novo UBE2A Mutations Are Recurrently Acquired during CML Progression and Interfere with Myeloid Differentiation Pathways
Authors: Vera Magistroni, Rocco Piazza, Mario Mauri, Caterina Mezzatesta, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David T Yeung, Sara Redaelli, Paul Wang, Alessandra Pirola, Luca Massimino, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini
Journal: Blood (2017)
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Authors: Yunpeng Yang, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jinyi Lang, Guangyuan Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Feng Lei, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiaojing Zhang, Jianjun Zou, Wenfeng Fang, Li Zhang
Journal: The Lancet Oncology (2021)
Mask use by adults with asthma in the era of covid 19
Authors: B. J. Polivka, L. Huntington-Moskos, S. M. Nyenhuis, K. Eldeirawi
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Rationale: The evidence that wearing masks greatly reduces the chance of becoming infected with COVID-19 is strongly supported, although not all masks confer similar protection. What is unknown is to what extent adults with asthma wear masks, the type of masks worn, and discomfort/problems encountered when wearing a mask. Method: Adults with asthma who previously responded to a survey concerning the impact of COVID-19 on their lives and indicated they were willing to participate in additional studies (N=712) were asked to complete a 50-item REDCap survey concerning their mask use. Survey items included the type of mask/face covering usually worm, how long a mask was usually worn, the practice of carrying an inhaler when wearing a mask, the extent to which problems/concerns were experienced when wearing a mask/face, COVID-19 status, asthma control, and open-ended questions concerning mask wearing. Results: Respondents (N=455) were primarily female (83%), white (90%), and college educated (74%). Few (5%) had been diagnosed with COVID-19. Most participants (98.5%) indicated they wore a mask/face covering when out in public. Most respondents (63%) reported wearing a mask 2 or fewer hours/day. The most common types of masks/facial coverings used were cloth mask with at least 2 layers and a surgical mask. Over half (52%) always/most of the time carried their inhaler when wearing a mask. Respondents with uncontrolled asthma (ACT less than or equal to 19) and those with a high school education or less were significantly less likely to wear a surgical mask and more likely to wear a cloth mask with only 1 layer. Respondents with uncontrolled asthma were significantly more likely to indicate problems breathing and anxiety when wearing a mask (See Figure). Several participants commented that while they do not like wearing a mask, not contracting COVID-19 was a strong incentive to wear a mask. Several respondents who wear masks for extended periods at work indicated the importance of taking a safe break from mask wearing to relieve the discomforts experienced. Conclusions: Adults with asthma are likely to wear a mask/face covering when in public and report having some problems/concerns breathing when wearing a mask. Those with uncontrolled asthma and those with less education were more likely to wear less effective masks/face coverings. Efforts are needed to assure the knowledge and means to secure the most effective masks are available to all adults with asthma.
From da Vinci to definitive diagnosis: how training in sports ultrasound harnesses sound, science and skill
Authors: Jon Patricios, Michael Rossiter, Corey Cunningham, Jane Fitzpatrick, Anja Hirschmueller, Thamsanqa Mweli, Beverly Roos, Jane S Thornton
Journal: British Journal of Sports Medicine (2021)

Viennese neurologist Dr Karl Dussik’s 1942 paper Uber die Moglichkeit hochfrequente mechanische schwingingen als diagnosticsches hilfsmittel zu verwerten (On the possibility of using ultrasound waves as a diagnostic aid)1 could be considered the precursor of modern ultrasound curricula, building on scientific findings that began with Leonardo da Vinci, who first recorded experiments listening to sound transmitted through water by placing a tube into the sea to evaluate what he could hear as early as 1490.

Medical use of ultrasound was popularised in gynaecology and obstetrics from the 1950s. Other fields such as cardiology, surgery, urology and vascular medicine followed in channelling the diagnostic power of ultrasound technology.2 Musculoskeletal medicine and the application of ultrasound in sports settings had a relatively late start. In 1996, Gibbon published the first textbook on the topic, “Musculoskeletal Ultrasound: The Essentials” describing a “mini-atlas of the normal and abnormal sonographic appearances of the adult joints”.3

The reach of musculoskeletal ultrasound into Sports and Exercise Medicine (SEM) practice and curricula is disparate, varying in several aspects including quality, regulation and accessibility. Such discrepancies may be further exaggerated by varying image resolution concomitant with equipment features and cost.

In the UK, ultrasound training is not a mandatory part of the SEM curriculum but is seen as an additional sub-speciality skill. It is usually achieved via an instructional course and then a written and practical assessment, leading to a Certificate of Competence. The …
Coronary Disease Association With ADAMTS7 Is Due to Protease Activity
Authors: Taiji Mizoguchi, Bryan T. MacDonald, Bidur Bhandary, Nicholas R. Popp, Dylan Laprise, Alessandro Arduini, Daniel Lai, Qiuyu Martin Zhu, Yi Xing, Virendar K. Kaushik, Sekar Kathiresan, Patrick T. Ellinor
Journal: Circulation Research (2021)

Rationale: Despite contemporary therapy, coronary artery disease (CAD) remains a leading cause of mortality. Genetic variants at ADAMTS7 have been associated with CAD and the loss of ADAMTS7 (a disintegrin and metalloproteinase with thrombospondin motifs 7) is protective for atherosclerosis. ADAMTS7 is a secreted metalloproteinase and complex proteoglycan; yet, the mechanism linking ADAMTS7 to CAD risk remains unresolved. Objective: To investigate the role of ADAMTS7 catalytic function in vascular smooth muscle cellular migration and during atherosclerosis. Methods and Results: We established a new purification strategy for full-length mouse ADAMTS7 and demonstrated the loss of activity in the catalytic mutant form of ADAMTS7. To test if the enzymatic activity of ADAMTS7 mediates atherosclerosis, we generated a catalytically inactive mutant mouse allele and compared it to the Adamts7 knockout. Using 2 models of atherosclerosis, we found that reducing either ADAMTS7 dosage or catalytic function decreased the burden of atherosclerosis. We demonstrate impaired vascular smooth muscle migration in both Adamts7 catalytic mutant and null cells using a lateral migration wound healing assay. Expression of the wild-type allele rescued the migration phenotype in Adamts7 null cells while expression of the catalytic mutant protein did not. We then characterized a human ADAMTS7 coding variant rs3825807 (Ser214Pro) associated with reduced CAD risk. This variant had a hypomorphic effect on ADAMTS7 secretion and migration of vascular smooth muscle cells, findings consistent with our mouse studies. Conclusions: We demonstrated that loss of ADAMTS7 catalytic function protects against atherosclerosis via phenotype switch of vascular smooth muscle cells and that the atherosclerosis protective effects could be mediated by a loss-of-function coding variant associated with CAD risk. In aggregate, we provide compelling evidence that dosage of ADAMTS7 and catalytic function are responsible for the atherosclerotic phenotype, suggesting that the catalytic domain would be an attractive therapeutic target for CAD.
Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US
Authors: Dana Stafkey-Mailey, Anuja Roy, Tasneem Lokhandwala, Jing Yuan, Pamela Landsman-Blumberg, Asif Siddiqui, Farhat Ghaznawi
Journal: Blood (2017)
The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia
Authors: Günalp Uzun, Karina Althaus, Anurag Singh, Peter Möller, Ulf Ziemann, Annerose Mengel, Peter Rosenberger, Martina Guthoff, Gabor C. Petzold, Jens Müller, Martin Büchsel, Katharina Feil, Hans Henkes, Nils Heyne, Matthias Maschke, Caroline Limpach, Simon Nagel, Ulrich J. Sachs, Falko Fend, Tamam Bakchoul
Journal: Blood (2021)
シクロホスファミドは,全身性の樹状細胞再活性化と免疫原性腫瘍アポトーシスの誘導を介して,I型インターフェロンとの相乗作用を示す
Authors: Schiavoni Giovanna, Sistigu Antonella, Valentini Mara, Mattei Fabrizio, Sestili Paola, Spadaro Francesca, Sanchez Massimo, Lorenzi Silvia, D’Urso Maria Teresa, Belardelli Filippo, Gabriele Lucia, Proietti Enrico, Bracci Laura
Journal: Cancer Research (2011)
A platelet-mimicking theranostic platform for cancer interstitial brachytherapy
Authors: Meng Lyu, Mingzhu Chen, Lujie Liu, Daoming Zhu, Xianjia Wu, Yang Li, Lang Rao, Zhirong Bao
Journal: Theranostics (2021)

Interstitial brachytherapy (BT) is a promising radiation therapy for cancer; however, the efficacy of BT is limited by tumor radioresistance. Recent advances in materials science and nanotechnology have offered many new opportunities for BT.
Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation.
Authors: Brian Allen, Edward Florez, Reza Sirous, Seth T Lirette, Michael Griswold, Erick M. Remer, Zhen J. Wang, Jacob E Bieszczad, Kelly L Cox, Ajit H. Goenka, Candace M Howard-Claudio, HyunSeon Kang, Sadhna B Nandwana, Rupan Sanyal, Atul B. Shinagare, J. Clark Henagen, Judd Storrs, Matthew S. Davenport, Brian I. Rini, Andrew Dennis Smith
Journal: Journal of Clinical Oncology (2017)

432 Background: In clinical trials and clinical practice, tumor response assessment with computed tomography (CT) defines critical end points in patients with metastatic disease treated with systemic agents. Methods to reduce errors and improve efficiency in tumor response assessment could improve patient care. Methods: Eleven readers from 10 different institutions independently categorized tumor response according to three different therapeutic response criteria using paired baseline and initial post-therapy CT studies from 20 randomly selected patients with metastatic renal cell carcinoma treated with sunitinib as part of a completed phase III multi-institutional study. Images were evaluated with a manual tumor response evaluation method (standard-of-care) and with computer-assisted response evaluation (CARE) that included stepwise guidance, interactive error-identification and correction methods, automated tumor metric extraction, calculations, response categorization, and data/image archival. A cross-over design, patient randomization, and two-week washout period were used to reduce recall bias. Comparative effectiveness metrics included error rate and mean patient evaluation time. Results: The standard-of-care method was on average associated with one or more errors in 30.5% (6.1/20) of patients while CARE had a 0.0% (0.0/20) error rate (p&lt;0.001). The most common errors were related to data transfer and arithmetic calculation. In patients with errors, the median number of error types was 1 (range 1-3). Mean patient evaluation time with CARE was twice as fast as the standard-of-care method (6.4 vs. 13.1 minutes, p&lt;0.001). Conclusions: Computer-assisted tumor response evaluation reduced errors and time of evaluation, indicating better overall effectiveness than manual tumor response evaluation methods that are the current standard-of-care.
만성 간질환에서 항섬유화 치료의 과거와 미래
Authors: 이영석 ( Young-Sok Lee )
Journal: Clinical and Molecular Hepatology (2006)

Hepatic fibrosis is characterized by the excessive accumulation of multiple matrix
components in the liver including the interstitial collagens, basement membrane collagens,
proteoglycans, and matrix glycoproteins. Activated hepatic stellate cells, portal fibroblasts, and
myofibroblasts are the major source of extracellular matrix in response to fibrogenic cytokines
such as TGF- . The fibrogenic process is dynamic and liver fibrosis is the net result of β
the imbalance between the collagen fiber synthesis and decomposition. The progress in
understanding fibrogenic mechanism provided the development of effective therapies to reverse
hepatic fibrosis and even cirrhosis. Removing the injurious stimuli, suppressing hepatic
inflammation, down-regulating stellate cell activation and promoting matrix degradation are
the mainstay of antifibrotic therapy. Many potential antifibrotic strategies based on apoptosis
of the activated stellate cells, drug targeting to the fibrogenic liver cells, and combination
therapy of multiple drugs in small doses are emerging but testing of their clinical efficacy and
safety remains to be clarified.
Bone Substitutes: 3D Printed Porous Methacrylate/Silica Hybrid Scaffold for Bone Substitution (Adv. Healthcare Mater. 12/2021)
Authors: Justin J. Chung, Jin Yoo, Brian S. T. Sum, Siwei Li, Soojin Lee, Tae Hee Kim, Zhenlun Li, Molly M. Stevens, Theoni K. Georgiou, Youngmee Jung, Julian R. Jones
Journal: Advanced Healthcare Materials (2021)

In article number 2100117 by Julian R. Jones, Youngmee Jung, and co-workers, star poly(MMAco-TMSPMA)-silica inorganic–organic hybrids are 3D printed to produce grid-like scaffolds with mechanical properties matching those of bone. The scaffolds respond well to cyclic mechanical tests and encourage bone formation in vivo.
<scp>Time‐Dependent</scp> Analysis of Risk of <scp>New‐Onset</scp> Heart Failure Among Patients With Polymyositis and Dermatomyositis
Authors: Chun‐Yu Lin, Hung‐An Chen, Tsai‐Ching Hsu, Chun‐Hsin Wu, Yu‐Jih Su, Chung‐Yuan Hsu
Journal: Arthritis & Rheumatology (2021)

To determine the risk and time trends of heart failure (HF) leading to hospitalization in individuals newly diagnosed as having polymyositis/dermatomyositis (PM/DM) relative to non-PM/DM controls at the general population level.A retrospective cohort study was conducted using data from a nationwide insurance database in Taiwan. Patients with incident PM/DM and without a history of HF were selected between 2000 and 2013. Unmatched and propensity score-matched cohorts were established separately. A multivariable Cox proportional hazards regression model was used to estimate the adjusted hazard ratio (HR) for the risk of HF in the unmatched cohort. In the propensity score-matched cohort, general population controls were selected and matched at a 1:1 ratio to the patients with PM/DM based on propensity scores, which accounted for the confounding factors of age, sex, index date (year) of first diagnosis, comorbidities, and medication usage. The cumulative incidence of HF was estimated using the Kaplan-Meier method. A stratified Cox proportional hazards model was used to calculate the HR for the risk of HF events at different follow-up time points among patients with PM/DM compared with non-PM/DM controls in the propensity score-matched cohort.In the unmatched cohort, the study assessed 2,025 patients with PM/DM and 196,109 general population controls. Results of multivariable Cox regression analysis, adjusted for age, sex, comorbidities, and medication usage, revealed a greater risk of HF leading to hospitalization in the PM/DM group than in the control group (adjusted HR 3.29, 95% confidence interval [95% CI] 2.60-4.18). After matching based on propensity score, a total of 1,997 pairs of PM/DM patients and general population controls were identified. In this propensity score-matched cohort, the cumulative incidence of HF in patients with PM/DM at 3 years, 5 years, and 10 years was 3.3%, 4.4%, and 7.4%, respectively. The absolute difference in HF risk in the PM/DM group compared with the control group was 1.8% at 3 years, 2.1% at 5 years, and 3.0% at 10 years. Compared with general population controls, patients with PM/DM exhibited an augmented risk of HF (HR 2.06, 95% CI 1.36-3.12). Analyses stratified according to follow-up time point revealed that the increased risk of HF persisted for up to 10 years after the PM/DM diagnosis.These results indicate that the risk of HF leading to hospitalization was increased in patients with PM/DM throughout the study period, supporting the need for greater vigilance in the monitoring of patients with PM/DM for the development of this potentially lethal complication.
Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
Authors: Edward S. Knock, Lilith K. Whittles, John A. Lees, Pablo N. Perez-Guzman, Robert Verity, Richard G. FitzJohn, Katy A. M. Gaythorpe, Natsuko Imai, Wes Hinsley, Lucy C. Okell, Alicia Rosello, Nikolas Kantas, Caroline E. Walters, Sangeeta Bhatia, Oliver J. Watson, Charlie Whittaker, Lorenzo Cattarino, Adhiratha Boonyasiri, Bimandra A. Djaafara, Keith Fraser, Han Fu, Haowei Wang, Xiaoyue Xi, Christl A. Donnelly, Elita Jauneikaite, Daniel J. Laydon, Peter J. White, Azra C. Ghani, Neil M. Ferguson, Anne Cori, Marc Baguelin
Journal: Science Translational Medicine (2021)

A SARS-CoV-2 transmission model fitted to surveillance data estimates virus transmissibility, infection severity, and the impact of interventions.
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
Authors: Youn Ho Shin, Jae Il Shin, Sung Yong Moon, Hyun Young Jin, So Young Kim, Jee Myung Yang, Seong Ho Cho, Sungeun Kim, Minho Lee, Youngjoo Park, Min Seo Kim, Hong-Hee Won, Sung Hwi Hong, Andreas Kronbichler, Ai Koyanagi, Louis Jacob, Lee Smith, Keum Hwa Lee, Dong In Suh, Seung Won Lee, Dong Keon Yon
Journal: The Lancet Rheumatology (2021)